Inflammatory bone loss: pathogenesis and therapeutic intervention (original) (raw)

• Sims, N. A. & Gooi, J. H. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin. Cell Dev. Biol. 19, 444–451 (2008).
  Article CAS PubMed Google Scholar
• Bodine, P. V. & Komm, B. S. Wnt signaling and osteoblastogenesis. Rev. Endocr. Metab. Disord. 7, 33–39 (2006).
  Article CAS PubMed Google Scholar
• Yavropoulou, M. P. & Yovos, J. G. Osteoclastogenesis — current knowledge and future perspectives. J. Musculoskelet. Neuronal. Interact. 8, 204–216 (2008).
  CAS PubMed Google Scholar
• Eriksen, E. F. Cellular mechanisms of bone remodeling. Rev. Endocr. Metab. Disord. 11, 219–227 (2010).
  Article PubMed PubMed Central Google Scholar
• Raisz, L. G. & Rodan, G. A. Pathogenesis of osteoporosis. Endocrinol. Metab. Clin. North Am. 32, 15–24 (2003).
  Article PubMed Google Scholar
• Frenkel, B. et al. Regulation of adult bone turnover by sex steroids. J. Cell Physiol. 224, 305–310 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Mosekilde, L. Primary hyperparathyroidism and the skeleton. Clin. Endocrinol. (Oxf.) 69, 1–19 (2008).
  Article CAS Google Scholar
• Bliuc, D. et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301, 513–521 (2009).
  Article CAS PubMed Google Scholar
• Johnell, O. et al. Mortality after osteoporotic fractures. Osteoporos. Int. 15, 38–42 (2004).
  Article CAS PubMed Google Scholar
• Grabowski, P. Physiology of bone. Endocr. Dev. 16, 32–48 (2009).
  Article CAS PubMed Google Scholar
• Holm, K. & Hedricks, C. Immobility and bone loss in the aging adult. Crit. Care Nurs. Q. 12, 46–51 (1989).
  Article CAS PubMed Google Scholar
• Michalakis, K., Peitsidis, P. & Ilias, I. Pregnancy- and lactation-associated osteoporosis: a narrative mini-review. Endocr. Regul. 45, 43–47 (2011).
  CAS PubMed Google Scholar
• Howe, T. E. et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database. Syst. Rev. CD000333 (2011).
• Sinaki, M. et al. The role of exercise in the treatment of osteoporosis. Curr. Osteoporos. Rep. 8, 138–144 (2010).
  Article PubMed Google Scholar
• Mundy, G. R. Osteoporosis and inflammation. Nutr. Rev. 65, S147–S151 (2007).
  Article PubMed Google Scholar
• Romas, E. & Gillespie, M. T. Inflammation-induced bone loss: can it be prevented? Rheum. Dis. Clin. North Am. 32, 759–773 (2006).
  Article PubMed Google Scholar
• Smolen, J. S. et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade. Ann. Rheum. Dis. 68, 823–827 (2009).
  Article CAS PubMed Google Scholar
• Gaur, T. et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J. Biol. Chem. 280, 33132–33140 (2005).
  Article CAS PubMed Google Scholar
• Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425, 577–584 (2003). This study provides an authoritative review of the signal transduction pathways mediated bythe transforming growth factor-β protein family, to which BMPs belong, which utilize SMADs as intracellular effectors of transcriptional regulation.
  Article CAS PubMed Google Scholar
• Qin, L. et al. Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J. Biol. Chem. 278, 19723–19731 (2003).
  Article CAS PubMed Google Scholar
• Bodine, P. V., Seestaller-Wehr, L., Kharode, Y. P., Bex, F. J. & Komm, B. S. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J. Cell Physiol. 210, 352–357 (2007).
  Article CAS PubMed Google Scholar
• Gazzerro, E. & Canalis, E. Bone morphogenetic proteins and their antagonists. Rev. Endocr. Metab. Disord. 7, 51–65 (2006).
  Article CAS PubMed Google Scholar
• Franceschi, R. T. & Xiao, G. Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J. Cell Biochem. 88, 446–454 (2003).
  Article CAS PubMed Google Scholar
• Zaidi, M. Skeletal remodeling in health and disease. Nature Med. 13, 791–801 (2007).
  Article CAS PubMed Google Scholar
• Lian, J. B. et al. Networks and hubs for the transcriptional control of osteoblastogenesis. Rev. Endocr. Metab. Disord. 7, 1–16 (2006).
  Article CAS PubMed Google Scholar
• Yamane, T. et al. Wnt signaling regulates hemopoiesis through stromal cells. J. Immunol. 167, 765–772 (2001).
  Article CAS PubMed Google Scholar
• Van Den Berg, D. J., Sharma, A. K., Bruno, E. & Hoffman, R. Role of members of the Wnt gene family in human hematopoiesis. Blood 92, 3189–3202 (1998).
  CAS PubMed Google Scholar
• van Amerongen, R. & Nusse, R. Towards an integrated view of Wnt signaling in development. Development 136, 3205–3214 (2009).
  Article CAS PubMed Google Scholar
• Fedi, P. et al. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J. Biol. Chem. 274, 19465–19472 (1999).
  Article CAS PubMed Google Scholar
• Kwack, M. H. et al. Dihydrotestosterone-inducible Dickkopf 1 from balding dermal papilla cells causes apoptosis in follicular keratinocytes. J. Invest. Dermatol. 128, 262–269 (2008).
  Article CAS PubMed Google Scholar
• Tian, E. et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349, 2483–2494 (2003).
  Article CAS PubMed Google Scholar
• Diarra, D. et al. Dickkopf-1 is a master regulator of joint remodeling. Nature Med. 13, 156–163 (2007).
  Article CAS PubMed Google Scholar
• Mao, B. et al. Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling. Nature 417, 664–667 (2002).
  Article CAS PubMed Google Scholar
• Veverka, V. et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J. Biol. Chem. 284, 10890–10900 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Romero, G. et al. Parathyroid hormone receptor directly interacts with Dishevelled to regulate β-catenin signaling and osteoclastogenesis. J. Biol. Chem. 285, 14756–14763 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Nakashima, K. et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17–29 (2002). This publication provides the first description of the role of osterix in osteoblast differentiation.
  Article CAS PubMed Google Scholar
• Koga, T. et al. NFAT and osterix cooperatively regulate bone formation. Nature Med. 11, 880–885 (2005).
  Article CAS PubMed Google Scholar
• Chang, J. et al. Inhibition of osteoblastic bone formation by nuclear factor-κB. Nature Med. 15, 682–689 (2009).
  Article CAS PubMed Google Scholar
• Krum, S. A., Chang, J., Miranda-Carboni, G. & Wang, C. Y. Novel functions for NFκB: inhibition of bone formation. Nature Rev. Rheumatol. 6, 607–611 (2010).
  Article CAS Google Scholar
• Gooi, J. H. et al. Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone 46, 1486–1497 (2010).
  Article CAS PubMed Google Scholar
• Yasuda, H. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95, 3597–3602 (1998). This was one of the initial studies describing RANKL and its pivotal osteoclastogenic role.
  Article CAS PubMed PubMed Central Google Scholar
• Murshed, M., Harmey, D., Millan, J. L., McKee, M. D. & Karsenty, G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev. 19, 1093–1104 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Bonewald, L. F. Osteocytes as dynamic multifunctional cells. Ann. NY Acad. Sci. 1116, 281–290 (2007).
  Article CAS PubMed Google Scholar
• Bonewald, L. F. & Johnson, M. L. Osteocytes, mechanosensing and Wnt signaling. Bone 42, 606–615 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Schneider, P., Meier, M., Wepf, R. & Muller, R. Towards quantitative 3D imaging of the osteocyte lacuno–canalicular network. Bone 47, 848–858 (2010).
  Article PubMed Google Scholar
• van Bezooijen, R. L., ten Dijke, P., Papapoulos, S. E. & Lowik, C. W. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 16, 319–327 (2005).
  Article CAS PubMed Google Scholar
• Murakami, M. et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260, 1808–1810 (1993). This paper clarifies the complexity of IL-6R molecules and signalling.
  Article CAS PubMed Google Scholar
• Rose-John, S., Scheller, J., Elson, G. & Jones, S. A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J. Leukoc. Biol. 80, 227–236 (2006).
  Article CAS PubMed Google Scholar
• Walker, E. C. et al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J. Clin. Invest. 120, 582–592 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Malaval, L., Liu, F., Vernallis, A. B. & Aubin, J. E. GP130/OSMR is the only LIF/IL-6 family receptor complex to promote osteoblast differentiation of calvaria progenitors. J. Cell Physiol. 204, 585–593 (2005).
  Article CAS PubMed Google Scholar
• Sims, N. A. & Walsh, N. C. gp130 cytokines and bone remodelling in health and disease. BMB Rep. 43, 513–523 (2010).
  Article CAS PubMed Google Scholar
• Manolagas, S. C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21, 115–137 (2000).
  CAS PubMed Google Scholar
• Hay, E., Lemonnier, J., Fromigue, O., Guenou, H. & Marie, P. J. Bone morphogenetic protein receptor IB signaling mediates apoptosis independently of differentiation in osteoblastic cells. J. Biol. Chem. 279, 1650–1658 (2004).
  Article CAS PubMed Google Scholar
• Bradford, P. G., Gerace, K. V., Roland, R. L. & Chrzan, B. G. Estrogen regulation of apoptosis in osteoblasts. Physiol. Behav. 99, 181–185 (2010).
  Article CAS PubMed Google Scholar
• Moriishi, T. et al. Overexpression of Bcl2 in osteoblasts inhibits osteoblast differentiation and induces osteocyte apoptosis. PLoS ONE 6, e27487 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• de Vernejoul, M. C. & Kornak, U. Heritable sclerosing bone disorders: presentation and new molecular mechanisms. Ann. NY Acad. Sci. 1192, 269–277 (2010).
  Article CAS PubMed Google Scholar
• Li, X. et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 23, 860–869 (2008).
  Article PubMed Google Scholar
• Teitelbaum, S. L. Bone resorption by osteoclasts. Science 289, 1504–1508 (2000).
  Article CAS PubMed Google Scholar
• Wagner, E. F. Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun). Ann. Rheum. Dis. 69 (Suppl. 1), 86–88 (2010).
  Article CAS Google Scholar
• Schonthaler, H. B., Guinea-Viniegra, J. & Wagner, E. F. Targeting inflammation by modulating the Jun/AP-1 pathway. Ann. Rheum. Dis. 70 (Suppl. 1), 109–112 (2011).
  Article CAS Google Scholar
• Shaulian, E. & Karin, M. AP-1 as a regulator of cell life and death. Nature Cell Biol. 4, E131–E136 (2002).
  Article CAS PubMed Google Scholar
• Koga, T. et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428, 758–763 (2004).
  Article CAS PubMed Google Scholar
• Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889–901 (2002).
  Article CAS PubMed Google Scholar
• Delaisse, J. M. et al. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc. Res. Tech. 61, 504–513 (2003).
  Article CAS PubMed Google Scholar
• Supanchart, C. & Kornak, U. Ion channels and transporters in osteoclasts. Arch. Biochem. Biophys. 473, 161–165 (2008).
  Article CAS PubMed Google Scholar
• Goldring, S. R., Roelke, M. S., Petrison, K. K. & Bhan, A. K. Human giant cell tumors of bone identification and characterization of cell types. J. Clin. Invest. 79, 483–491 (1987).
  Article CAS PubMed PubMed Central Google Scholar
• Dougall, W. C. et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412–2424 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Hofbauer, L. C. et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15, 2–12 (2000).
  Article CAS PubMed Google Scholar
• Wiktor-Jedrzejczak, W. et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc. Natl Acad. Sci. USA 87, 4828–4832 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Grigoriadis, A. E. et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443–448 (1994). This study reveals the essential role of the transcription factor AP1, and particularly its component FOS, in osteoclastogenesis.
  Article CAS PubMed Google Scholar
• Binder, N. B. et al. Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nature Med. 15, 417–424 (2009).
  Article CAS PubMed Google Scholar
• Kim, M. S., Day, C. J. & Morrison, N. A. MCP-1 is induced by receptor activator of nuclear factor-κB ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J. Biol. Chem. 280, 16163–16169 (2005).
  Article CAS PubMed Google Scholar
• Kong, Y. Y. et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304–309 (1999). This publication links the adaptive immune system to osteoclast activation and inflammatory bone destruction.
  Article CAS PubMed Google Scholar
• Roggia, C. et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl Acad. Sci. USA 98, 13960–13965 (2001). This study provides evidence of the role of TNF in osteoporosis induced by oestrogen deficiency.
  Article CAS PubMed PubMed Central Google Scholar
• Kapinas, K. & Delany, A. M. MicroRNA biogenesis and regulation of bone remodeling. Arthritis Res. Ther. 13, 220 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Sugatani, T., Vacher, J. & Hruska, K. A. A microRNA expression signature of osteoclastogenesis. Blood 117, 3648–3657 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kapinas, K., Kessler, C., Ricks, T., Gronowicz, G. & Delany, A. M. miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J. Biol. Chem. 285, 25221–25231 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Sugatani, T. & Hruska, K. A. Impaired micro-RNA pathways diminish osteoclast differentiation and function. J. Biol. Chem. 284, 4667–4678 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Gough, A. K., Lilley, J., Eyre, S., Holder R. L. & Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344, 23–27 (1994).
  Article CAS PubMed Google Scholar
• Romas, E. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates. Best Pract. Res. Clin. Rheumatol. 19, 1065–1079 (2005).
  Article CAS PubMed Google Scholar
• Roldan, J. F., del, Rincón, I. & Escalante, A. Loss of cortical bone from the metacarpal diaphysis in patients with rheumatoid arthritis: independent effects of systemic inflammation and glucocorticoids. J. Rheumatol. 33, 508–516 (2006).
  PubMed Google Scholar
• Gravallese, E. M. et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 152, 943–951 (1998). This study reveals the role of synovial-derived osteoclasts in local bone damage (erosions) in patients with rheumatoid arthritis.
  CAS PubMed PubMed Central Google Scholar
• Garcia-Carrasco, M. et al. Osteoporosis in patients with systemic lupus erythematosus. Isr. Med. Assoc. J. 11, 486–491 (2009).
  PubMed Google Scholar
• Grisar, J. et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J. Rheumatol. 29, 1430–1436 (2002).
  PubMed Google Scholar
• Ali, T., Lam, D., Bronze, M. S. & Humphrey, M. B. Osteoporosis in inflammatory bowel disease. Am. J. Med. 122, 599–604 (2009).
  Article PubMed PubMed Central Google Scholar
• Paganelli, M. et al. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm. Bowel Dis. 13, 416–423 (2007).
  Article PubMed Google Scholar
• Bianchi, M. L. & Bardella, M. T. Bone in celiac disease. Osteoporos. Int. 19, 1705–1716 (2008).
  Article PubMed Google Scholar
• Cashman, K. D. Altered bone metabolism in inflammatory disease: role for nutrition. Proc. Nutr. Soc. 67, 196–205 (2008).
  Article CAS PubMed Google Scholar
• Shead, E. F., Haworth, C. S., Barker, H., Bilton, D. & Compston, J. E. Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. J. Cyst. Fibros. 9, 93–98 (2010).
  Article CAS PubMed Google Scholar
• Dam, T. T., Harrison, S., Fink, H. A., Ramsdell, J. & Barrett-Connor, E. Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos. Int. 21, 1341–1349 (2010).
  Article PubMed Google Scholar
• Yoshihara, A., Seida, Y., Hanada, N. & Miyazaki, H. A longitudinal study of the relationship between periodontal disease and bone mineral density in community-dwelling older adults. J. Clin. Periodontol. 31, 680–684 (2004).
  Article PubMed Google Scholar
• Redlich, K. et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am. J. Pathol. 164, 543–555 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Lin, C. L., Moniz, C., Chambers, T. J. & Chow, J. W. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 111, 1263–1271 (1996).
  Article CAS PubMed Google Scholar
• Mattila, K. J., Valle, M. S., Nieminen, M. S., Valtonen, V. V. & Hietaniemi, K. L. Dental infections and coronary atherosclerosis. Atherosclerosis 103, 205–211 (1993).
  Article CAS PubMed Google Scholar
• Reddy, M. S. Oral osteoporosis: is there an association between periodontitis and osteoporosis? Compend. Contin. Educ. Dent. 23, 21–28 (2002).
  PubMed Google Scholar
• Kawai, T. et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am. J. Pathol. 169, 987–998 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Teng, Y. T. et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J. Clin. Invest. 106, R59–R67 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V. K. IL-17 and Th17 cells. Annu. Rev. Immunol. 27, 485–517 (2009).
  Article CAS PubMed Google Scholar
• Hundorfean, G., Neurath, M. F. & Mudter, J. Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease. Inflamm. Bowel Dis. 18, 180–186 (2012).
  Article PubMed Google Scholar
• Wong, P. K. et al. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 54, 158–168 (2006). This study provides evidence of the role of IL-6 and associated IL-17 production on osteoclast generation.
  Article CAS PubMed Google Scholar
• Dinarello, C. A. Interleukin-1 and interleukin-1 antagonism. Blood 77, 1627–1652 (1991).
  CAS PubMed Google Scholar
• Tracey K. J. & Cerami, A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 45, 491–503 (1994).
  Article CAS PubMed Google Scholar
• Dinarello, C. A. et al. Tumor necrosis factor (cachectin) is an endogeneous pyrogen and induces production of interleukin 1. J. Exp. Med. 163, 1433–1450 (1986).
  Article CAS PubMed Google Scholar
• Naka, T., Nishimoto, N. & Kishimoto, T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 4 (Suppl. 3), 233–242 (2002).
  Article Google Scholar
• Kishimoto, T. IL-6: from its discovery to clinical applications. Int. Immunol. 22, 347–352 (2010).
  Article CAS PubMed Google Scholar
• Wallach, D. et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 17, 331–367 (1999).
  Article CAS PubMed Google Scholar
• Goeddel, D. V. Signal transduction by tumor necrosis factor: the Parker B. Francis Lectureship. Chest 116 (Suppl. 1), 69–73 (1999).
  Article Google Scholar
• Sethi, G., Sung, B. & Aggarwal, B. B. TNF: a master switch for inflammation to cancer. Front. Biosci. 13, 5094–5107 (2008).
  Article CAS PubMed Google Scholar
• Ikejima, T., Okusawa, S., Ghezzi, P., van der Meer, J. W. & Dinarello, C. A. Interleukin-1 induces tumor necrosis factor (TNF) in human peripheral blood mononuclear cells in vitro and a circulating TNF-like activity in rabbits. J. Infect. Dis. 162, 215–223 (1990).
  Article CAS PubMed Google Scholar
• Legendre, F., Bogdanowicz, P., Boumediene, K. & Pujol, J. P. Role of interleukin 6 (IL-6)/IL-6R-induced signal tranducers and activators of transcription and mitogen-activated protein kinase/extracellular signal-related kinase in upregulation of matrix metalloproteinase and ADAMTS gene expression in articular chondrocytes. J. Rheumatol. 32, 1307–1316 (2005).
  PubMed Google Scholar
• Rowan, A. D. et al. Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis Rheum. 44, 1620–1632 (2001).
  Article CAS PubMed Google Scholar
• Shingu, M. et al. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin. Exp. Immunol. 94, 145–149 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Solis-Herruzo, J. A. et al. Interleukin-6 increases rat metalloproteinase-13 gene expression through stimulation of activator protein 1 transcription factor in cultured fibroblasts. J. Biol. Chem. 274, 30919–30926 (1999).
  Article CAS PubMed Google Scholar
• Richards, C., Gauldie, J. & Baumann, H. Cytokine control of acute phase protein expression. Eur. Cytokine Netw. 2, 89–98 (1991).
  CAS PubMed Google Scholar
• Dinarello, C. A. Interleukin-1 and the pathogenesis of the acute-phase response. N. Engl. J. Med. 311, 1413–1418 (1984).
  Article CAS PubMed Google Scholar
• Kushner, I. Regulation of the acute phase response by cytokines. Perspect. Biol. Med. 36, 611–622 (1993).
  Article CAS PubMed Google Scholar
• Andus, T., Geiger, T., Hirano, T., Kishimoto, T. & Heinrich, P. C. Action of recombinant human interleukin 6, interleukin 1β and tumor necrosis factor α on the mRNA induction of acute-phase proteins. Eur. J. Immunol. 18, 739–746 (1988).
  Article CAS PubMed Google Scholar
• Zhang, Y. H., Lin, J. X. & Vilcek, J. Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence. Mol. Cell Biol. 10, 3818–3823 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Everaerdt, B., Brouckaert, P. & Fiers, W. Recombinant IL-1 receptor antagonist protects against TNF-induced lethality in mice. J. Immunol. 152, 5041–5049 (1994).
  CAS PubMed Google Scholar
• Devlin, R. D., Reddy, S. V., Savino, R., Ciliberto, G. & Roodman G. D. IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures. J. Bone Miner. Res. 13, 393–399 (1998).
  Article CAS PubMed Google Scholar
• Ma, T. et al. Human interleukin-1-induced murine osteoclastogenesis is dependent on RANKL, but independent of TNF-α. Cytokine 26, 138–144 (2004).
  Article CAS PubMed Google Scholar
• Lee, Z. H. et al. IL-1α stimulation of osteoclast survival through the PI 3-kinase/Akt and ERK pathways. J. Biochem. 131, 161–166 (2002).
  Article CAS PubMed Google Scholar
• Kobayashi, K. et al. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL–RANK interaction. J. Exp. Med. 191, 275–286 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Kotake, S. et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11, 88–95 1996.
  Article CAS PubMed Google Scholar
• De Benedetti, F. et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 54, 3551–3563 (2006).
  Article CAS PubMed Google Scholar
• Lam, J. et al. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481–1488 (2000). This report reveals the role of the pro-inflammatory cytokine TNF in osteoclastogenesis.
  Article CAS PubMed PubMed Central Google Scholar
• Abu-Amer, Y., Ross, F. P., Edwards, J. & Teitelbaum S. L. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its p55 receptor. J. Clin. Invest. 100, 1557–1565 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Bluml, S. et al. Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum. 62, 1608–1619 (2010). This study dissects the osteoclastogenic effects of TNF signals, showing that these effects are mediated via activation of TNF receptor 1 rather than TNF receptor 2, and that the latter may have protective effects.
  Article CAS PubMed Google Scholar
• Zhang, Y. H., Heulsmann, A., Tondravi, M. M., Mukherjee, A. & Abu-Amer, Y. Tumor necrosis factor-α (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J. Biol. Chem. 276, 563–568 (2001).
  Article CAS PubMed Google Scholar
• Ravetch, J. V. & Bolland, S. IgG Fc receptors. Annu. Rev. Immunol. 19, 275–290 (2001).
  Article CAS PubMed Google Scholar
• Zou, W. et al. Syk, c-Src, the αvβ3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J. Cell Biol. 176, 877–888 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Vignery, A. Macrophage fusion: the making of osteoclasts and giant cells. J. Exp. Med. 202, 337–340 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Zvaifler, N. J. Rheumatoid synovitis. An extravascular immune complex disease. Arthritis Rheum. 17, 297–305 (1974).
  Article CAS PubMed Google Scholar
• Weissmann, G. Rheumatoid arthritis and systemic lupus erythematosus as immune complex diseases. Bull. NYU Hosp. Jt Dis. 67, 251–253 (2009).
  PubMed Google Scholar
• Brown, E. E., Edberg, J. C. & Kimberly, R. P. Fc receptor genes and the systemic lupus erythematosus diathesis. Autoimmunity 40, 567–581 (2007).
  Article CAS PubMed Google Scholar
• Mocsai, A. et al. The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc. Natl Acad. Sci. USA 101, 6158–6163 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Scott, D. L., Symmons, D. P., Coulton, B. L. & Popert, A. J. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1, 1108–1111 (1987).
  Article CAS PubMed Google Scholar
• Aringer, M. & Smolen, J. S. Therapeutic blockade of TNF in patients with SLE — promising or crazy? Autoimmunity Rev. 18 May 2011 (doi:10.1016/j.autrev.2011.05.001.2011).
• Sokolove, J., Zhao, X., Chandra, P. E. & Robinson, W. H. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor. Arthritis Rheum. 63, 53–62 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Guerne, P. A., Carson, D. A. & Lotz, M. IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro. J. Immunol. 144, 499–505 (1990).
  CAS PubMed Google Scholar
• van Gool, J., van Vugt, H., Helle, M. & Aarden, L. A. The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. Clin. Immunol. Immunopathol. 57, 200–210 (1990).
  Article CAS PubMed Google Scholar
• Chrousos, G. P. The hypothalamic–pituitary–adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 332, 1351–1362 (1995).
  Article CAS PubMed Google Scholar
• Perlstein, R. S., Whitnall, M. H., Abrams, J. S., Mougey, E. H. & Neta, R. Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology 132, 946–952 (1993).
  Article CAS PubMed Google Scholar
• Rachon, D., Mysliwska, J., Suchecka-Rachon, K., Wieckiewicz, J. & Mysliwski, A. Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. J. Endocrinol. 172, 387–395 (2002).
  Article CAS PubMed Google Scholar
• Poli, V. et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13, 1189–1196 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Girasole, G., Passeri, G., Jilka, R. L. & Manolagas, S. C. Interleukin-11: a new cytokine critical for osteoclast development. J. Clin. Invest. 93, 1516–1524 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Okamoto, H. et al. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 40, 1096–1105 (1997).
  Article CAS PubMed Google Scholar
• Sasai, M. et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 42, 1635–1643 (1999).
  Article CAS PubMed Google Scholar
• Gilbert, L. et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2αA) is inhibited by tumor necrosis factor-α. J. Biol. Chem. 277, 2695–2701 (2002).
  Article CAS PubMed Google Scholar
• Gilbert, L. C., Rubin, J. & Nanes, M. S. The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis. Am. J. Physiol. Endocrinol. Metab. 288, E1011–E1018 (2005).
  Article CAS PubMed Google Scholar
• Kaneki, H. et al. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J. Biol. Chem. 281, 4326–4333 (2006).
  Article CAS PubMed Google Scholar
• Abbas, S., Zhang, Y. H., Clohisy, J. C. & Abu-Amer, Y. Tumor necrosis factor-α inhibits pre-osteoblast differentiation through its type-1 receptor. Cytokine 22, 33–41 (2003).
  Article CAS PubMed Google Scholar
• Mukai, T. et al. TNF-α inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. Biochem. Biophys. Res. Commun. 356, 1004–1010 (2007).
  Article CAS PubMed Google Scholar
• Ding, J. et al. TNF-α and IL-1β inhibit RUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. Life Sci. 84, 499–504 (2009).
  Article CAS PubMed Google Scholar
• Hughes, F. J. & Howells, G. L. Interleukin-6 inhibits bone formation in vitro. Bone Miner. 21, 21–28 (1993).
  Article CAS PubMed Google Scholar
• Hughes, F. J. & Howells, G. L. Interleukin-11 inhibits bone formation in vitro. Calcif. Tissue Int. 53, 362–364 (1993).
  Article CAS PubMed Google Scholar
• Li, X. et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280, 19883–19887 (2005).
  Article CAS PubMed Google Scholar
• Winkler, D. G. et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22, 6267–6276 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Mason, J. J. & Williams, B. O. SOST and DKK: antagonists of LRP family signaling as targets for treating bone disease. J. Osteoporos. 2010, 460120 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Viswanathan, A. & Sylvester, F. A. Chronic pediatric inflammatory diseases: effects on bone. Rev. Endocr. Metab. Disord. 9, 107–122 (2008).
  Article PubMed Google Scholar
• Capriles, V. D., Martini, L. A. & Areas, J. A. Metabolic osteopathy in celiac disease: importance of a gluten-free diet. Nutr. Rev. 67, 599–606 (2009).
  Article PubMed Google Scholar
• Payne, J. B. & Golub, L. M. Using tetracyclines to treat osteoporotic/osteopenic bone loss: from the basic science laboratory to the clinic. Pharmacol. Res. 63, 121–129 (2011).
  Article CAS PubMed Google Scholar
• Elborn, J. S. How can we prevent multisystem complications of cystic fibrosis? Semin. Respir. Crit. Care Med. 28, 303–311 (2007).
  Article PubMed Google Scholar
• Haugeberg, G., Conaghan, P. G., Quinn, M. & Emery, P. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 68, 1898–1901 (2009).
  Article CAS PubMed Google Scholar
• Strand, V. & Simon, L. S. Low dose glucocorticoids in early rheumatoid arthritis. Clin. Exp. Rheumatol. 21 (Suppl. 31), 186–190 (2003).
  Google Scholar
• Kim, H. J. et al. Glucocorticoids suppress bone formation via the osteoclast. J. Clin. Invest. 116, 2152–2160 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Hoes, J. N. et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann. Rheum. Dis. 66, 1560–1567 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Teitelbaum, S. L., Seton, M. P. & Saag, K. G. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum. 63, 325–328 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Lange, U., Teichmann, J., Muller-Ladner, U. & Strunk, J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study. Rheumatology (Oxford) 44, 1546–1548 (2005).
  Article CAS Google Scholar
• Bernstein, M., Irwin, S. & Greenberg, G. R. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am. J. Gastroenterol. 100, 2031–2035 (2005).
  Article CAS PubMed Google Scholar
• Veerappan, S. G., O'Morain, C. A., Daly, J. S. & Ryan, B. M. Review article: the effects of antitumour necrosis factor-a on bone metabolism in inflammatory bowel disease. Aliment. Pharmacol. Ther. 33, 1261–1272 (2011).
  Article CAS PubMed Google Scholar
• Kremer, J. M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 63, 609–621 (2011).
  Article CAS PubMed Google Scholar
• Ito, H. et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126, 989–996 (2004).
  Article CAS PubMed Google Scholar
• Hsu, B., Zhou, B., Smolen, J. S. & Weinblatt, M. Proof-of-concept for CNTO 136, a human anti-interleukin-6 monoclonal antibody, in a multicenter, randomized, double-blind, placebo-controlled, Phase 2 study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann. Rheum. Dis. 70 (Suppl. 3), 459 (2011).
  Google Scholar
• Mease, P. et al. Inhibition of IL-6 with ALD518 improves disease activity in rheumatoid arthritis in a randomized, double-blind, placebo-controlled, dose ranging Phase 2 clinical trial. Ann. Rheum. Dis. 69 (Suppl. 3), 98 (2011).
  Google Scholar
• Hickling, M., Golor, G., Juillon, A., Shaw, S. & Kretsos, K. Safety and pharmacokinetics of CDP6038, an anti-IL-6 monoclonal antibody, administered by subcutaneous injection and intravenous infusion to healthy male volunteers: a Phase 1 study. Ann. Rheum. Dis. 70 (Suppl. 3), 471 (2011).
  Google Scholar
• Nam, J. L. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis. 69, 976–986 (2010).
  Article CAS PubMed Google Scholar
• Baltzer, A. W. et al. Gene therapy for osteoporosis: evaluation in a murine ovariectomy model. Gene Ther. 8, 1770–1776 (2001).
  Article CAS PubMed Google Scholar
• Genovese, M. et al. Secukinumab (ain457) showed a rapid decrease of disease activity in patients with active rheumatoid arthritis including those with high inflammatory burden. Ann. Rheum. Dis. 70 (Suppl. 3), 472 (2011).
  Google Scholar
• Bluml, S. et al. Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum. 63, 1281–1288 (2011).
  Article CAS PubMed Google Scholar
• Yang, M. & Mattes, J. Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs. Pharmacol. Ther. 117, 94–104 (2008).
  Article CAS PubMed Google Scholar
• Smolen J. S. & Steiner, G. Therapeutic strategies for rheumatoid arthritis. Nature Rev. Drug Discov. 2, 473–488 (2003).
  Article CAS Google Scholar
• Westhovens, R. et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 68, 1870–1877 (2009).
  Article CAS PubMed Google Scholar
• Tak, P. P. et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann. Rheum. Dis. 70, 39–46 (2011).
  Article CAS PubMed Google Scholar
• Hein, G. et al. Influence of rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study. Rheumatol Int. 31, 269–272 (2011).
  Article CAS PubMed Google Scholar
• van der Heijde, D. et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: a 24-month Phase 3 study. [meeting abstract] Arthritis Rheum. 63 (Suppl. 10), 2592 (2011).
  Google Scholar
• Weinblatt, M. E. et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363, 1303–1312 (2010).
  Article CAS PubMed Google Scholar
• Massey, D. C., Bredin, F. & Parkes, M. Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 57, 1294–1296 (2008).
  Article CAS PubMed Google Scholar
• Cejka, D. et al. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Arthritis Rheum. 62, 2294–2302 (2010).
  Article CAS PubMed Google Scholar
• Westenfeld, R. et al. Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis —implications for post-transplantation bone disease. Nephrol. Dial. Transplant. 12, 4115–4123 (2011).
  Article CAS Google Scholar
• Dobashi, Y., Watanabe, Y., Miwa, C., Suzuki, S. & Koyama, S. Mammalian target of rapamycin: a central node of complex signaling cascades. Int. J. Clin. Exp. Pathol. 4, 476–495 (2011).
  CAS PubMed PubMed Central Google Scholar
• Markman, B., Dienstmann, R. & Tabernero, J. Targeting the PI3K/Akt/mTOR pathway — beyond rapalogs. Oncotarget 1, 530–543 (2010).
  PubMed PubMed Central Google Scholar
• Kim, J. E. & Chen, J. Regulation of peroxisome proliferator-activated receptor-γ activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 53, 2748–2756 (2004).
  Article CAS PubMed Google Scholar
• Wan, Y. PPARγ in bone homeostasis. Trends Endocrinol. Metab. 21, 722–728 (2010).
  Article CAS PubMed Google Scholar
• Glantschnig, H., Fisher, J. E., Wesolowski, G., Rodan, G. A. & Reszka, A. A. M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death. Differ. 10, 1165–1177 (2003).
  Article CAS PubMed Google Scholar
• Garrett, I. R. et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J. Clin. Invest. 111, 1771–1782 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, D., Frezza, M., Schmitt, S., Kanwar, J. & Dou, P. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr. Cancer Drug Targets 11, 239–253 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• von Metzler, I. et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 21, 2025–2034 (2007).
  Article CAS PubMed Google Scholar
• Zavrski, I. et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem. Biophys. Res. Commun. 333, 200–205 (2005).
  Article CAS PubMed Google Scholar
• Hongming, H. & Jian, H. Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. Leuk. Res. 33, 115–122 (2009).
  Article CAS PubMed Google Scholar
• Schmidt, N. et al. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 59, 896–906 (2010).
  Article CAS PubMed Google Scholar
• Lee, S. W., Kim, J. H., Park, Y. B. & Lee, S. K. Bortezomib attenuates murine collagen-induced arthritis. Ann. Rheum. Dis. 68, 1761–1767 (2009).
  Article CAS PubMed Google Scholar
• Yannaki, E. et al. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis Rheum. 62, 3277–3288 (2010).
  Article CAS PubMed Google Scholar
• Russell, R. G. Bisphosphonates: the first 40 years. Bone 49, 2–19 (2011).
  Article CAS PubMed Google Scholar
• Lin, C. L., Moniz, C. & Chow, J. W. Treatment with fluoride or bisphosphonates prevents bone loss associated with colitis in the rat. Calcif. Tissue Int. 67, 373–377 (2000).
  Article CAS PubMed Google Scholar
• Eggelmeijer, F. et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum. 39, 396–402 (1996).
  Article CAS PubMed Google Scholar
• Kwak, H. B. et al. Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss. Biol. Pharm. Bull. 32, 1193–1198 (2009).
  Article CAS PubMed Google Scholar
• Watts, N. B. & Diab, D. L. Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab. 95, 1555–1565 (2010).
  Article CAS PubMed Google Scholar
• McClung, M. R. et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354, 821–831 (2006).
  Article CAS PubMed Google Scholar
• Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756–765 (2009).
  Article CAS PubMed Google Scholar
• Cohen, S. B. et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial. Arthritis Rheum. 58, 1299–1309 (2008). The results from this trial provide proof of concept that selectively targeting osteoclasts prevents local inflammatory bone loss but does not affect inflammation or cartilage damage.
  Article CAS PubMed Google Scholar
• Dore, R. K. et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann. Rheum. Dis. 69, 872–875 (2010).
  Article CAS PubMed Google Scholar
• Adler, R. A. & Gill, R. S. Clinical utility of denosumab for treatment of bone loss in men and women. Clin. Interv. Aging 6, 119–124 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Saad, F. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled Phase III trials in cancer patients with bone metastases. Ann. Oncol. 10 Oct 2011 (doi:10.1093/annonc/mdr435).
• Takahata, M., Awad, H. A., O'Keefe, R. J., Bukata, S. V. & Schwarz, E. M. Endogenous tissue engineering: PTH therapy for skeletal repair. Cell Tissue Res. 31 May 2011 (doi:10.1007/s00441-011-1188-4).
• Vincent, C. et al. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFα induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J. Bone Miner. Res. 24, 1434–1449 (2009).
  Article CAS PubMed Google Scholar
• Heiland, G. R. et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann. Rheum. Dis. 69, 2152–2159 (2010). This study reveals the efficacy of blocking DKK1 on inflammatory bone loss in an experimental model.
  Article CAS PubMed Google Scholar
• Betts, A. M. et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J. Pharmacol. Exp. Ther. 333, 2–13 (2010).
  Article CAS PubMed Google Scholar
• Ominsky, M. S. et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J. Bone Miner. Res. 26, 1012–1021 (2011).
  Article CAS PubMed Google Scholar
• Tian, X. et al. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone 47, 529–533 (2010).
  Article CAS PubMed Google Scholar
• Li, X. et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24, 578–588 (2009).
  Article CAS PubMed Google Scholar
• Rickels, M. R., Zhang, X., Mumm, S. & Whyte, M. P. Oropharyngeal skeletal disease accompanying high bone mass and novel LRP5 mutation. J. Bone Miner. Res. 20, 878–885 (2005).
  Article CAS PubMed Google Scholar
• Zeckey, C., Hildebrand, F., Frink, M. & Krettek, C. Heterotopic ossifications following implant surgery — epidemiology, therapeutical approaches and current concepts. Semin. Immunopathol. 33, 273–286 (2011).
  Article PubMed Google Scholar
• Boraiah, S., Paul, O., Hawkes, D., Wickham, M. & Lorich, D. G. Complications of recombinant human BMP-2 for treating complex tibial plateau fractures: a preliminary report. Clin. Orthop. Relat. Res. 467, 3257–3262 (2009).
  Article PubMed PubMed Central Google Scholar
• Balemans, W., Cleiren, E., Siebers, U., Horst, J. & Van Hul, W. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone 36, 943–947 (2005).
  Article CAS PubMed Google Scholar
• Hoff, M. et al. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. BMC Musculoskelet. Disord. 12, 54 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Eklund, S. A. & Burt, B. A. Risk factors for total tooth loss in the United States; longitudinal analysis of national data. J. Public Health Dent. 54, 5–14 (1994).
  Article CAS PubMed Google Scholar
• Gladman, D. D. et al. Consensus on a core set of domains for psoriatic arthritis. J. Rheumatol. 34, 1167–1170 (2007).
  PubMed Google Scholar
• van der Heijde, D. et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum. 47, 215–218 (2002).
  Article PubMed Google Scholar
• Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. & Emery, P. New therapies for the treatment of rheumatoid arthritis. Lancet 370, 1861–1874 (2007).
  Article CAS PubMed Google Scholar
• Smolen, J. S. et al. Evidence of radiographic benefit of infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of the ATTRACT trial. Arthritis Rheum. 52, 1020–1030 (2005).
  Article CAS PubMed Google Scholar
• Smolen, J. S. et al. The need for prognosticators in rheumatoid arthritis. Biological and clinical markers — where are we now? Arthritis Res. Ther. 10, 208 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Smolen, J. S., Martinez-Avila, J. C. & Aletaha, D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its antiinflammatory effects: disassociation of the link between inflammation and destruction. Ann. Rheum. Dis. 25 Nov 2011 (doi:10.1136/annrheumdis-2011-200395).
• Mattes, J., Yang, M. & Foster, P. S. Regulation of microRNA by antagomirs: a new class of pharmacological antagonists for the specific regulation of gene function? Am. J. Respir. Cell. Mol. Biol. 36, 8–12 (2007).
  Article CAS PubMed Google Scholar
• Sims, N. A. et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum. 50, 2338–2346 (2004).
  Article CAS PubMed Google Scholar
• Herrak, P. et al. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum. 50, 2327–2337 (2004).
  Article CAS PubMed Google Scholar
• Jarrett, S. J. et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum. 54, 1410–1414 (2006).
  Article CAS PubMed Google Scholar
• Schett, G. et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum. 48, 2042–2051 (2003).
  Article CAS PubMed Google Scholar
• Schett, G. et al. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum. 52, 1604–1611 (2005).
  Article CAS PubMed Google Scholar
• Aletaha, D., Funovits, J. & Smolen, J. S. Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. Ann. Rheum. Dis. 70, 733–739 (2011).
  Article PubMed Google Scholar
• van der Heijde, D. et al. Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis. Arthritis Res. Ther. 9, R62 (2007).
  Article PubMed PubMed Central Google Scholar
• Machold, K. P. et al. Very recent onset arthritis — clinical, laboratory and radiological findings during the first year of disease. J. Rheumatol. 29, 2278–2287 (2002).
  PubMed Google Scholar
• Plant, M. J., Jones, P. W., Saklatvala, J., Ollier, W. E. & Dawes, P. T. Patterns of radiological progression in rheumatoid arthritis: results of an 8 year prospective study. J. Rheumatol. 25, 417–426 (1998).
  CAS PubMed Google Scholar
• Van der Heijde, D. M. Joint erosions and patients with early rheumatoid arthritis. Br. J. Rheumatol. 34,(Suppl. 2), 74–78 (1995).
  Article PubMed Google Scholar
• Redlich, K. et al. Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 46, 785–792 (2002).
  Article CAS PubMed Google Scholar
• Muller-Ladner, U. et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am. J. Pathol. 149, 1607–1615 (1996).
  CAS PubMed PubMed Central Google Scholar
• Colucci, S. et al. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFα, and IL-7 in an in vitro model derived from human psoriatic arthritis. J. Pathol. 212, 47–55 (2007).
  Article CAS PubMed Google Scholar
• Redlich, K. et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J. Clin. Invest. 110, 1419–1427 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Partsch, G. et al. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol. 24, 518–523 (1997).
  CAS PubMed Google Scholar
• Gortz, B. et al. Arthritis induces lymphocytic bone marrow inflammation and endosteal bone formation. J. Bone Miner. Res. 19, 990–998 (2004).
  Article CAS PubMed Google Scholar
• Jimenez-Boj, E. et al. Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum. 56, 1118–1124 (2007).
  Article PubMed Google Scholar
• Arnett, F. C. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315–324 (1988).
  Article CAS PubMed Google Scholar
• Shimizu, S., Shiozawa, S., Shiozawa, K., Imura, S. & Fujita, T. Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum. 28, 25–31 (1985).
  Article CAS PubMed Google Scholar
• Mansson, B., Gulfe, A., Geborek, P., Heinegard, D. & Saxne, T. Release of cartilage and bone macromolecules into synovial fluid: differences between psoriatic arthritis and rheumatoid arthritis. Ann. Rheum. Dis. 60, 27–31 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Furie, R. et al. A Phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918–3930 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Hsu, B., Sheng, S., Smolen, J. & Weinblatt, M. Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, Phase 2 study of sirukumab, a human anti-interleukin-6 monoclonal antibody, in active rheumatoid arthritis patients despite methotrexate therapy. [meeting abstract] Arthritis Rheum. 63 (Suppl. 10), 2631 (2011).
  Google Scholar
• Griffiths, C. E. et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362, 118–128 (2010).
  Article CAS PubMed Google Scholar
• Taylor, P. C. et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann. Rheum. Dis. 70, 2119–2125 (2011).
  Article CAS PubMed Google Scholar
• van Vollenhoven, R. F., Kinnman, N., Vincent, E., Wax, S. & Bathon, J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a Phase II, randomized, placebo-controlled trial. Arthritis Rheum. 63, 1782–1792 (2011).
  Article CAS PubMed Google Scholar
• Hartung, H. P. & Kieseier, B. C. Atacicept: targeting B cells in multiple sclerosis. Ther. Adv. Neurol. Disord. 3, 205–216 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Fulciniti, M. et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114, 371–379 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Cusick, T. et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner. Res. 23 Nov 2011 (doi:10.1002/jbmr.1477).
• Eisman, J. A. et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J. Bone Miner. Res. 26, 242–251 (2011).
  Article CAS PubMed Google Scholar